A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients

Inclusion Criteria: * Patients of both genders, between 18 to 60 years of age, with bronchial asthma for at least 6 months and history of exercise induced bronchospasm * Patients with FEV1 ≥ 70% of predicted after withholding short-acting β agonists for at least 8 hours prior to testing * Screening exercise challenge demonstrates that the patient experiences a fall in FEV1 of ≥ 20% * Non-smokers with free from the usage of nicotine-containing products at least for a year prior to screening Exclusion Criteria: * Previous history of life-threatening asthma, respiratory tract infection and/or exacerbation of asthma within 6 weeks prior to the first screening visit * History of being unable to tolerate or complete an exercise challenge and clinically significant multiple drug or food allergies * Past or present disorders and diseases including, but are not limited to cardiovascular, malignancy, hepatic, renal, hematological, neurological, psychiatric, endocrine, or pulmonary other than asthma * Patients with Seasonal Allergic Rhinitis (SAR) or seasonal allergic asthma,with significant symptoms that may confound study assessment * Significant safety laboratory, ECG, or vital sign abnormalities that would place the patient at undue risk during the study procedures